<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20220120080500Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-20-1492_h_dec_2.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 24.1.2022c(2022) 507 (final)</p></section><section><header>commission implementing decisionof 24.1.2022
 amending the conditional marketing authorisation granted by decision c(2020) 
 9284(final) for “tecartus - autologous anti-cd19-transduced cd3+ cells”, an orphan 
 medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 24.1.2022
 amending the conditional marketing authorisation granted by decision c(2020) 
 9284(final) for “tecartus - autologous anti-cd19-transduced cd3+ cells”, an orphan 
 medicinal product for human use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1,having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular articles 17(2) and 20(7)(a) thereof,
 having regard to directive 2001/83/ec of the european parliament and of the council of 6 
 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof,
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by kite pharma eu b.v. in accordance with regulation (ec) no 
 1234/2008 and in accordance with article 61(3) of directive 2001/83/ec,
 having regard to the opinion of the european medicines agency, formulated on 16 
 december 2021 by the committee for medicinal products for human use,
 whereas:
 (1)
 the european medicines agency&apos;s opinion is favourable to the variation of the terms 
 of the decision granting the marketing authorisation as submitted by the marketing 
 authorisation holder.
 (2)
 decision c(2020) 9284(final) should therefore be amended accordingly. the union 
 register of medicinal products should also be updated.
 1oj l 136, 30.4.2004, p. 1.2oj l 334, 12.12.2008, p. 7.3oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(3)for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2020) 9284(final) should therefore be replaced.
 has adopted this decision:
 article 1decision c(2020) 9284(final) is amended as follows:1) annex i is replaced by the text set out in annex i to this decision;
 2) annex ii is replaced by the text set out in annex ii to this decision;
 3) annex iii is replaced by the text set out in annex iii to this decision.
 article 2this decision is addressed to kite pharma eu b.v., tufsteen 1, 2132 nt hoofddorp, nederland.
 done at brussels, 24.1.2022
 for the commissionsandra gallina
 director-general</p></section></body></xml>